TiGenix Rheumatoid Arthritis Trial Moves to Randomized Stage

TiGenix NV (TIG) got approval from the independent Safety Monitoring Board to move its Phase IIa clinical trial in rheumatoid arthritis into randomized recruitment.

“This decision is based on the analysis of the safety data from patients treated in the study’s first cohort,” TiGenix said today in an e-mailed statement.

To contact the editor responsible for this story: Andrew Clapham at aclapham@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.